Singulex to Present at 34th Annual Cowen Healthcare Conference
ALAMEDA, Calif.--(BUSINESS WIRE)--Singulex, Inc., the developer and leading provider of Single Molecule Counting (SMC™) technology for clinical diagnostics and scientific discovery, today announced that Guido Baechler, the Company’s President and CEO, will present a corporate overview at the 34th Annual Cowen and Company Healthcare Conference. Mr. Baechler’s presentation will take place on Tuesday, March 4th at 11:30 am ET at the Boston Marriott Copley Place in Boston, MA.
About Singulex, Inc.
Singulex is the developer and leading provider of Single Molecule Counting (SMC™) technology for clinical diagnostics and scientific discovery. Singulex’s proprietary SMC technology enables physicians and scientists to detect biomarkers of disease that were previously undetectable. Powered by SMC technology, Singulex’s ultrasensitive immunoassay solutions and lab testing services are transforming patient care from reactive disease treatment to proactive health management and fueling the discovery and development of new therapeutics.
Singulex provides SMC technology to leading pharmaceutical R&D laboratories, clinical research organizations (CROs) and academic institutions around the world through its Research-Use-Only Erenna® Immunoassay System. The Singulex Clinical Lab Testing Services consist of a CLIA-licensed and CAP-accredited laboratory that currently provides a comprehensive menu of advanced cardiovascular disease testing utilizing SMC. Singulex is developing the Singulex Clinical Diagnostic System, a fully-automated in vitro diagnostics system that will bring the benefits of its SMC technology to hospital and reference labs worldwide. For further information, please visit www.singulex.com.